PARTNERS WITH
tepotinib
TKI- MET Inhibitor
MECHANISM OF ACTION
MECHANISM OF KIDNEY INJURY
pseduo-AKI; competitive inhibition of creatinine secretion in the renal tubules
CLINICAL KIDNEY SYNDROME
Other side effects include; edema and hyponatremia
CARDIOVASCULAR ADVERSE EFFECTS
LYTE ABNORMALITIES
elevated creatinine and hyponatremia
RISK FACTORS
MITIGATION STRATEGIES
SUGGESTIONS
Check cystatin C level
NOTES/COMMENTS
A median increase in serum creatinine of 31% was observed 21 days after initiation
PHARMACOKINETICS
Molecular Weight
547.05 g/mol
Volume of Distribution
1,038 L (24.3%).
Plasma Protein Binding
98%
Metabolism
Bioavailability
Half-life elimination
32 hours
Time to peak
Excretion
85% in feces (45% unchanged) and 13.6% in urine (7% unchanged)
Dialyzable?
No dosage modification is recommended when eGFR 30 to 89 mL/min
No established recommendation if eGFR < 30 ml/min
REF:
https://doi.org/10.1093/ckj/sfac180
https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/214096s000lbl.pdf
PATHOLOGY SLIDES:
ENTRY UPDATES:
Mar 30, 2023